ArticleFrontiers in oncology2026

Progression-free survival outcomes of PARP inhibitors in ovarian cancer: an exploratory analysis of treatment heterogeneity based on organ vulnerability.

Xing Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.